search
Back to results

NESBID: Neuro-Stimulation of the Brain in Depression (NESBID)

Primary Purpose

Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant, Transcranial Direct Current Stimulation

Status
Active
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Transcranial direct current stimulation
Sponsored by
University of Alberta
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depressive Disorder, Major

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Currently suffering from an MDE with a score on the Montgomery-Åsberg Depression Rating Scale (MADRS) greater than 34 (signifying severe depression)
  • Have ultra treatment resistant MDD (defined as failure to remit despite adequate trials with five antidepressants, or failure to remit with ECT, or failure to remit with ketamine)

Exclusion Criteria:

  • Have been diagnosed with psychosis, an addiction disorder (other than nicotine), borderline personality disorder, or antisocial personality disorder, as these conditions could interfere with adherence to the study protocol
  • Are currently using a herbal compound or known NMDA-modulating agent, as these substances could interfere with the induction of LTP and thereby limit the effectiveness of tDCS
  • Are pregnant, as tDCS has not been adequately studied in this population
  • Have an electronic implant, cardiac dysrhythmia, seizure disorder, neurological disorder, or neurosurgical history, as the safety of electrical stimulation with tDCS cannot be assured given these comorbidities

Sites / Locations

  • Grey Nuns Community Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Active transcranial direct current stimulation

Sham transcranial direct current stimulation

Arm Description

Active transcranial direct current stimulation (tDCS), delivered at 2 mA and for 30 minutes, on sequential weekdays, for a total of 30 sessions. Participants will continue to receive their usual pharmacotherapy and psychotherapy.

Sham transcranial direct current stimulation (tDCS), which will ramp up to 2 mA over 17 s, and then ramp down to and remain at 0.3 mA for the remainder of the 30 minute session. The short period of active stimulation is included to stimulate the somatic sensations of active therapy. The trickle current at 0.3 mA is necessary to measure electrode contact and prevent investigators from deducing that the device is no longer active. Participants will receive the sham therapy on sequential weekdays for a total of 30 sessions. Participants will continue to receive their usual pharmacotherapy and psychotherapy.

Outcomes

Primary Outcome Measures

Montgomery-Asberg Depression Rating Scale (MADRS)
An observer-assessed score of depression severity. The total is scored from 0 to 60, with higher scores representing greater depression severity

Secondary Outcome Measures

Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR16)
A participant-assessed measurement of depression severity. The total is scored from 0 to 27, with higher scores indicating greater depression severity.
World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)
Change in the World Health Organization Disability Assessment Schedule score
Exploratory language analysis
Change in language characteristics, based on recorded interviews
Lexical decision making task
Performance on a task in which patients much distinguish real from fictitious words as quickly as possible
tDCS adverse events scale
Adverse events as assessed on a scale derived from a systematic review on side effects that may be associated with tDCS
FIBSER
Frequency, Intensity, and Burden of Side-Effects Rating Scale
PRISE
Patient-Rated Inventory of Side-Effects Scale
YMRS
Young Mania Rating Scale, included to capture treatment-related manic or hypomanic switches

Full Information

First Posted
July 8, 2019
Last Updated
May 30, 2023
Sponsor
University of Alberta
Collaborators
Alberta Health services
search

1. Study Identification

Unique Protocol Identification Number
NCT04159012
Brief Title
NESBID: Neuro-Stimulation of the Brain in Depression
Acronym
NESBID
Official Title
NESBID: Neuro-Stimulation of the Brain in Depression. A Randomized, Controlled Clinical Trial of Transcranial Direct Current Stimulation Augmentation, as Compared to Sham Therapy, in the Treatment of Ultra-resistant Major Depressive Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
September 1, 2020 (Actual)
Primary Completion Date
December 1, 2023 (Anticipated)
Study Completion Date
December 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Alberta
Collaborators
Alberta Health services

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In Canada, approximately 20% of patients with Major Depressive Disorder (MDD) have treatment-resistance and fail to respond to trials of pharmacotherapy or psychotherapy. Although the treatment of choice has historically consisted of electroconvulsive therapy (ECT), this is not always feasible or practical, and carries a risk of side-effects that may be unacceptable to certain patients. In this pragmatic, multi-site, placebo-controlled and double-blinded clinical trial, participants with ultra treatment-resistant MDD will be randomized to receive either active or sham transcranial direct current stimulation in addition to their usual treatment. Ultra treatment-resistant depression will be operationally defined as MDD that has failed to respond to at least five previous trials of antidepressants at sufficient doses, or ECT, or ketamine. Patients will receive a total of 30 active or sham treatment sessions (5 per week), for 30 minutes per session. In both groups, the anode will be placed over the left dorsolateral prefrontal cortex (position F3), and the cathode over the right dorsolateral prefrontal cortex (position F4). Patients in the sham group will receive electrical stimulation at 2 mA for less than 30 seconds, whereas patients in the active group will receive that level of stimulation for the entire duration of treatment. The study's primary outcome is the change in score on a clinician-graded depression inventory (the Montgomery-Asberg Depression Rating Scales). Secondary outcomes include change in scores on a self-administered depression rating scale and measurement of function scale. Information on language ability will also be collected, as will data on side-effects of treatment. Scores will be collected before the trial start, after every 10 sessions, and one month after trial completion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant, Transcranial Direct Current Stimulation, Electric Stimulation Therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Active transcranial direct current stimulation
Arm Type
Experimental
Arm Description
Active transcranial direct current stimulation (tDCS), delivered at 2 mA and for 30 minutes, on sequential weekdays, for a total of 30 sessions. Participants will continue to receive their usual pharmacotherapy and psychotherapy.
Arm Title
Sham transcranial direct current stimulation
Arm Type
Sham Comparator
Arm Description
Sham transcranial direct current stimulation (tDCS), which will ramp up to 2 mA over 17 s, and then ramp down to and remain at 0.3 mA for the remainder of the 30 minute session. The short period of active stimulation is included to stimulate the somatic sensations of active therapy. The trickle current at 0.3 mA is necessary to measure electrode contact and prevent investigators from deducing that the device is no longer active. Participants will receive the sham therapy on sequential weekdays for a total of 30 sessions. Participants will continue to receive their usual pharmacotherapy and psychotherapy.
Intervention Type
Device
Intervention Name(s)
Transcranial direct current stimulation
Other Intervention Name(s)
Sooma tDCS
Intervention Description
A Sooma transcranial direct current stimulator, using carbon electrodes, a reusable cap (to promote reproducible electrode placement), and disposable sponges that will be soaked in normal saline. The anode will be positioned over the left dorsolateral prefrontal cortex (position F3 on the 10-20 the International EEG system), and the cathode will be positioned over the right dorsolateral prefrontal cortex (position F4).
Primary Outcome Measure Information:
Title
Montgomery-Asberg Depression Rating Scale (MADRS)
Description
An observer-assessed score of depression severity. The total is scored from 0 to 60, with higher scores representing greater depression severity
Time Frame
Baseline, after 2 weeks, after 4 weeks, after 6 weeks/trial completion, and 1 month after trial completion
Secondary Outcome Measure Information:
Title
Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR16)
Description
A participant-assessed measurement of depression severity. The total is scored from 0 to 27, with higher scores indicating greater depression severity.
Time Frame
Baseline, after 2 weeks, after 4 weeks, after 6 weeks/trial completion, and 1 month after trial completion
Title
World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)
Description
Change in the World Health Organization Disability Assessment Schedule score
Time Frame
Baseline, after 2 weeks, after 4 weeks, after 6 weeks/trial completion, and 1 month after trial completion
Title
Exploratory language analysis
Description
Change in language characteristics, based on recorded interviews
Time Frame
Baseline and after 6 weeks/trial completion
Title
Lexical decision making task
Description
Performance on a task in which patients much distinguish real from fictitious words as quickly as possible
Time Frame
Baseline and after 6 weeks/trial completion
Title
tDCS adverse events scale
Description
Adverse events as assessed on a scale derived from a systematic review on side effects that may be associated with tDCS
Time Frame
Baseline, after 2 weeks, after 4 weeks, after 6 weeks/trial completion, and 1 month after trial completion
Title
FIBSER
Description
Frequency, Intensity, and Burden of Side-Effects Rating Scale
Time Frame
Baseline, after 2 weeks, after 4 weeks, after 6 weeks/trial completion, and 1 month after trial completion
Title
PRISE
Description
Patient-Rated Inventory of Side-Effects Scale
Time Frame
Baseline, after 2 weeks, after 4 weeks, after 6 weeks/trial completion, and 1 month after trial completion
Title
YMRS
Description
Young Mania Rating Scale, included to capture treatment-related manic or hypomanic switches
Time Frame
Baseline, after 2 weeks, after 4 weeks, after 6 weeks/trial completion, and 1 month after trial completion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Currently suffering from an MDE with a score on the Montgomery-Åsberg Depression Rating Scale (MADRS) greater than 34 (signifying severe depression) Have ultra treatment resistant MDD (defined as failure to remit despite adequate trials with five antidepressants, or failure to remit with ECT, or failure to remit with ketamine) Exclusion Criteria: Have been diagnosed with psychosis, an addiction disorder (other than nicotine), borderline personality disorder, or antisocial personality disorder, as these conditions could interfere with adherence to the study protocol Are currently using a herbal compound or known NMDA-modulating agent, as these substances could interfere with the induction of LTP and thereby limit the effectiveness of tDCS Are pregnant, as tDCS has not been adequately studied in this population Have an electronic implant, cardiac dysrhythmia, seizure disorder, neurological disorder, or neurosurgical history, as the safety of electrical stimulation with tDCS cannot be assured given these comorbidities
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Serdar M Dursun, MD, PhD
Organizational Affiliation
University of Alberta
Official's Role
Principal Investigator
Facility Information:
Facility Name
Grey Nuns Community Hospital
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6L 5X8
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Individual participant data will not be made available to other researchers.
Citations:
PubMed Identifier
33729165
Citation
Suleman R, Tucker BV, Dursun SM, Demas ML. The Neurostimulation of the Brain in Depression Trial: Protocol for a Randomized Controlled Trial of Transcranial Direct Current Stimulation in Treatment-Resistant Depression. JMIR Res Protoc. 2021 Mar 17;10(3):e22805. doi: 10.2196/22805.
Results Reference
derived

Learn more about this trial

NESBID: Neuro-Stimulation of the Brain in Depression

We'll reach out to this number within 24 hrs